Apixaban and Limiting Aspirin for Patients With Atrial Fibrillation, Percutaneous Coronary Intervention, and Multimorbidity
Related Experiment Video
Updated: Jun 8, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Konstantin A Krychtiuk1, Renato D Lopes1,2, Daniel M Wojdyla1
1Duke Clinical Research Institute, Durham, North Carolina, USA.
Insights
Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) benefit from apixaban plus a P2Y12 inhibitor, regardless of their comorbidity level. This treatment strategy is safe and effective for managing bleeding and ischemic risks.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Patients with atrial fibrillation (AF) following acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) face elevated risks of bleeding and ischemic events, particularly those with multiple comorbidities.
- Multimorbidity significantly increases the complexity of managing these high-risk patients.
Purpose of the Study:
- To analyze the safety and efficacy of different antithrombotic regimens in patients with varying degrees of multimorbidity undergoing treatment for AF post-ACS and/or PCI.
- To evaluate the impact of multimorbidity on clinical outcomes in this patient population.
Main Methods:
- A post-hoc analysis of the AUGUSTUS randomized controlled trial was conducted.
- Patients were stratified into no (0-2), moderate (3-4), and high (≥5) comorbidity groups.
- The study assessed interactions between multimorbidity and antithrombotic strategies (apixaban vs. VKA, aspirin vs. placebo) concerning bleeding and ischemic events.
Main Results:
- Higher rates of major or clinically relevant nonmajor bleeding (ISTH criteria) were observed in patients with moderate and high multimorbidity compared to those with no multimorbidity.
- No significant interactions were found between the level of multimorbidity and the antithrombotic regimens (apixaban vs. VKA or aspirin vs. placebo) for major bleeding, death, hospitalization, or ischemic events.
Conclusions:
- The findings support the consistent use of apixaban in combination with a P2Y12 inhibitor for patients with AF and ACS/PCI.
- This therapeutic approach is recommended irrespective of the patient's multimorbidity status, offering a reliable strategy for managing both bleeding and ischemic risks.
Background:
Patients with atrial fibrillation (AF) after an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) with multiple comorbidities are at increased risk for bleeding and ischemic events.
Objectives:
This post-hoc analysis of AUGUSTUS describes the safety and efficacy of antithrombotic regimens in patients with multimorbidity.
Methods:
AUGUSTUS was a 2 × 2 factorial, randomized controlled trial evaluating the safety of apixaban vs vitamin K antagonists (VKA) (open-label) and aspirin vs placebo (double-blind) in patients with AF and ACS and/or PCI treated with a P2Y12 inhibitor. Patients were categorized as having no multimorbidity (0-2 comorbidities), moderate multimorbidity (3-4 comorbidities), or high multimorbidity (≥5 comorbidities). The associations between multimorbidity and clinical outcomes and interactions with antithrombotic regimens were tested.
Results:
Of 4,493 patients (97.4%) with available comorbidity data, 1,897 (42.2%) had no multimorbidity, 2,110 (47%) had moderate, and 486 (10.8%) had high multimorbidity. Patients with moderate (HR: 1.23; 95% CI: 1.02-1.47) and high (HR: 1.98; 95% CI: 1.55-2.54) multimorbidity had higher rates of International Society on Thrombosis and Haemostasis (ISTH) major or clinically relevant nonmajor (CRNM) bleeding compared to patients with no multimorbidity. No significant interaction between multimorbidity and apixaban vs vitamin K antagonists was observed for ISTH major bleeding/CRNM (P int = 0.415), death or hospitalization (P int = 0.092), or death or ischemic event (P int = 0.299). Similarly, no significant interaction between multimorbidity and aspirin vs placebo was seen for ISTH major bleeding/CRNM (P int = 0.261), death or hospitalization (P int = 0.646), or death or ischemic event (P int = 0.608).
Conclusions:
Our findings support the standard use of apixaban plus a P2Y12 inhibitor in patients with AF and ACS/PCI, irrespective of the presence of multimorbidity.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...